Results 41 to 50 of about 208,684 (196)

Eye symptoms in patients with benign thyroid diseases

Scientific Reports, 2021
Thyroid diseases may cause a variety of functional and structural body changes, including eye and vision abnormalities, which can have a negative impact on a patient’s well-being. However, only a few studies on the impact of other benign thyroid diseases
Nadia Sawicka-Gutaj, Paulina Ziółkowska, Klaudia Wojciechowska, Sara Shawkat, Agata Czarnywojtek, Wojciech Warchoł, Jerzy Sowiński, Ewelina Szczepanek-Parulska, Marek Ruchała   +8 more
doaj   +1 more source

The Clinical Characteristics of Thyroid Orbitopathy in Thyroid Dysfunction Patients in Korea

, 2008
PURPOSE: To investigate the clinical manifestation of thyroid orbitopathy among patients with thyroid dysfunction. METHODS: A cross-sectional study was conducted at 24 general hospitals in Korea.
이상열
core   +1 more source

The relation between clinical response and quality of life improvement after treatment with intravenous methylprednisolone in Graves' orbitopathy

Acta Ophthalmologica, EarlyView.
Abstract Background Quality of life (QoL) is a key outcome in Graves' orbitopathy (GO), but prior studies have reported overall QoL changes without evaluating whether improvements occur specifically in patients who achieve objective clinical response.
Gijsbert J. Hötte, Willem A. Dik, Ronald O. B. de Keizer, Sodaba Khatab, M. Medici, Sigrid M. A. Swagemakers, Peter J. van der Spek, P. Martin van Hagen, Dion Paridaens   +8 more
wiley   +1 more source

Correlation between Intraocular Pressure and Thickness of Extraocular Muscles, the Severity and Activity of Thyroid-associated Orbitopathy

Folia Medica, 2019
Aim: To establish the correlation between intraocular pressure (IOP) and thickness of extraocular muscles (EOM), the severity and activity of thyroid-associated orbitopathy (TAO).
Stoyanova Nina Staneva, Konareva-Kostianeva Marieta, Mitkova-Hristova Vesela, Angelova Irina   +3 more
doaj   +1 more source

Tears as a Source of Biomarkers in the Diagnosis of Graves’ Orbitopathy

Biomolecules, 2022
Thyroid eye disease (TED) is a poorly understood autoimmune manifestation of thyroid diseases most commonly associated with Graves’ disease. Due to a lack of specific biomarkers and uncertain signs and symptoms, Graves’ orbitopathy (GO) is challenging to
Diana Bajkowska, Małgorzata Szelachowska, Angelika Buczyńska, Adam Jacek Krętowski, Katarzyna Siewko   +4 more
doaj   +1 more source

PROTEOMICS OF ORBITAL TISSUE IN THYROID-ASSOCIATED ORBITOPATHY.

, 2015
A potentially altered protein expression profile in orbital tissue from patients with thyroid-associated orbitopathy (TAO) is ...
Pfeiffer, N, Wolters, D, Planck, Tereza, Grus, F H, Lantz, Mikael, Brorson, Håkan, Ponto, K A, Matheis, N, Pitz, S, Kahaly, G J, Shahida, Bushra, Brorson, Håkan,, Planck, Tereza,, Lantz, Mikael,, Lund University., Shahida, Bushra,   +15 more
core   +1 more source

A Tear Metabolomic Profile Showing Increased Ornithine Decarboxylase Activity and Spermine Synthesis in Thyroid-Associated Orbitopathy [PDF]

, 2022
About half of patients with Graves’ disease develop an orbitopathy related to an inflammatory expansion of the periorbital adipose tissue and muscles. We used a targeted metabolomic approach measuring 188 metabolites by mass spectrometry to compare
Gohier, Philippe, Juan Manuel Chao de la Barca, Geoffrey Urbanski, Assad, Sophie, Ferré, Marc, Billiet, Benjamin, Jeanne Muller, Philippe Gohier, Marc Ferré, Gilles Simard, Pascal Reynier, Urbanski, Geoffrey, Anaïs Vautier, Muller, Jeanne, Simard, Gilles, Tessier, Lydie, Céline Wetterwald, Benjamin Billiet, Faure, Justine, Vautier, Anaïs, Odile Blanchet, Blanchet, Odile, de la Barca, Juan Manuel Chao, Sophie Assad, Delphine Mirebeau-Prunier, Wetterwald, Céline, Mirebeau-Prunier, Delphine, Patrice Rodien, Reynier, Pascal, Rodien, Patrice, Justine Faure, Lydie Tessier   +31 more
core   +1 more source

Diagnostic Options in Graves' or Non‐Graves' Thyrotoxicosis: A Review for Clinical Practice

Clinical Endocrinology, Volume 105, Issue 6, Page 603-609, December 2026.
ABSTRACT Objective Distinguishing Graves' disease (GD) from the other causes of thyrotoxicosis is essential for appropriate management. The clinical phenotype of GD has evolved over time and is currently more heterogenous and milder than in the past. Consequently, the differential diagnosis of thyrotoxicosis is often challenging.
Lorenzo Scappaticcio, Pierpaolo Trimboli, Paola Caruso, Chiara Porcellini, Daniela Forestiere, Maria Ida Maiorino, Katherine Esposito, Giuseppe Bellastella   +7 more
wiley   +1 more source

Role of teprotumumab in the treatment of active moderate-to-severe Graves’ orbitopathy

European Thyroid Journal, 2023
Graves’ orbitopathy (GO), also named thyroid-associated orbitopathy (TAO) or thyroid eye disease (TED), is an autoimmune inflammatory disease of the orbit and the most important extrathyroidal manifestation of Graves’ disease (1).
Luigi Bartalena
doaj   +1 more source

Periorbital Fat Loss From Prostaglandin Analogues: Dermatologic and Cosmetic Considerations

Journal of Cosmetic Dermatology, Volume 25, Issue 11, November 2026.
ABSTRACT Background Topical prostaglandin (PG) analogues, originally developed as first‐line therapies for glaucoma, are increasingly used in dermatology and cosmetic settings to promote eyelash and eyebrow growth. However, their use has been associated with prostaglandin‐associated periorbitopathy (PAP), a constellation of adverse effects including ...
Lily Kaufman, Aliza Khuhro, Sierra Schwierking, Lilia Valentic, Sonja Kobayashi, Lauren Malley, Olivia Ueltschi, Lucy Rose, Brittany Dulmage   +8 more
wiley   +1 more source